

Scott A. Fretzin, MD

Dawes Fretzin Clinical Research Group, LLC

7910 North Shadeland Avenue
Indianapolis, Indiana 46250
Phone (317) 516-5030
Fax (317) 516-5031
Email: DFCRGFretzin@ecommunity.com

Dawes Fretzin Dermatology Group, LLC

7910 North Shadeland Avenue
Indianapolis, Indiana 46250
Phone (317) 516-5000
Fax (317) 516-5031

Education

Indiana University School of Medicine (Indianapolis, IN)
Dermatology Residency, 1997

University of Chicago Pritzker School of Medicine (Chicago, IL)
Internal Medicine Internship, 1994

University of Chicago Pritzker School of Medicine (Chicago, IL)
Medical Doctorate, 1993

Washington University (St. Louis, MO)
Bachelor of Arts in Philosophy, 1989

Professional Experience

Marian University (Indianapolis, IN)
Clinical Assistant Professor, March 2016- Present

Dawes Fretzin Clinical Research Group, LLC (Indianapolis, IN)
Investigator, 2004-Present


Dawes Fretzin Dermatology Group, LLC (Indianapolis, IN)
Dermatologist, 1999-Present
Investigator, 2000-Present

Indiana University School of Medicine (Indianapolis, IN)
Volunteer Assistant Professor Clinical Dermatology, May 2011- Present

Bellflower County Clinic (Indianapolis, IN)
Dermatologist (part-time), 1997-April 2013

Indiana University School of Medicine (Indianapolis, IN)
Clinical Assistant Professor, 1997- May 2011

Dawes Dermatology Group (Indianapolis, IN)
Dermatologist, 1997-99



6/16/26

Scott A. Fretzin, MD

Honors and Awards

1996 Honorable Mention, Young Investigators Competition, Dermatol Surg
1992 Alpha Omega Alpha (AOA)
1989 Phi Beta Kappa
1989 Graduate with College Honors
1988 Genetics Society of America Summer Research Fellowship
1987-88 Scholarship and Leadership Award, Kappa Sigma National Fraternity

License/Certifications

Board Certified in Dermatology, 1997
Indiana State License #01044060
ACLS Certified
CITI GCP Certification

Professional Societies

American Academy of Dermatology
Indiana Dermatologic Society
American Medical Association

Articles and Publications

Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled study. Lindsay S. Ackerman, MD, Bethanee J. Schlosser, MD, PhD, Tianyu Zhan, PhD, Vimal H. Prajapati, MD, Scott Fretzin, MD, Hidetoshi Takahashi, MD, PhD, Xiaohong Huang, PhD, Heidi S. Camp, PhD, Alexa B. Kimball, MD, MPH JAMA Dermatol, Published online December 1, 2024

Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis - The LITE Randomized Clinical Trial. Joel M. Gelfand, MD; April Armstrong, MD; Henry W. Lim, MD; et al Steven R. Feldman, MD, PhD; Sandra M. Johnson, MD; W. C. Cole Claiborne, MD; Robert . Kalb, MD; Jeannette Jakus, MD; Aaron R. Mangold, MD; R. Hal Flowers, MD; Tina Bhutani, MD; John Durkin, MD; Jerry Bagel, MD; Scott Fretzin, MD; Michael P. Sheehan, MD; James Krell, MD; Margo Reeder, MD; Jessica Kaffenberger, MD; Francisca Kartono, DO; Junko Takeshita, MD, PhD; Alisha M. Bridges, BS; Eric Fielding, MBA; Umbereen S. Nehal, MD; Kenneth L. Schaecher, MD; Leah M. Howard, JD; Guy S. Eakin, PhD; Suzette Báez, MPH; Brooke E. Bishop, MPH; Robert C. Fitzsimmons Jr, MS; Maryte Papadopoulos, MBE; William B. Song, BS; Kristin A. Linn, PhD; Rebecca A. Hubbard, PhD; Daniel B. Shin, PhD; Kristina Callis Duffin, MD Author Affiliations JAMA Dermatol. Published online September 25, 2024

Scott A. Fretzin, MD

Articles and Publications – continued

- Kroman NJ., Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Nyirady J, Williams N., Mordin, M, Trying S.
“Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis.” Journal of Dermatological Treatment 2016 Nov 21, Volume 28 2017 Issue 5. 384-389.
- Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS, McColm J, Katcharian A, Cueto I, White T, Banerjee S, Hoffman RW. **“IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.”** J Allergy Clin Immunol. 2012 Jul;130(1):145-154.e9. Epub 2012 Jun 5.
- Gottlieb, A., Menter, A., Mendelsohn, A., Yaung-Kaung, S., Guzzo, C., Fretzin, S., Kunynetz, R., Kavanaugh, A. **“Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.”** Lancet, 2009 Feb 21; 373:633.
- Papp, K., Bressinck, R., Fretzin, S., Goffe, B., Kempers, S., Gordon, K., Caro, I., Walicke, P., Wang, X., Mentor, A. **“Safety of efalizumab in adults with chronic Moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial.”** International Journal of Dermatology, May 2006; Vol 45, Number 5: 605-614.
- Crowley, J., Fretzin, S., Sobell, J. **“New Treatment Options for Psoriasis Involving the Hands and Feet.”** Biologic Bulletin, March 2006.
- Fretzin, S. **“Recent Advances in the Treatment of Psoriasis with Efalizumab Therapy.”** US Dermatology Review, 2006 Issue II: 12-14.
- Fretzin, S. **“Managing Cases of Chronic, Moderate-to-Severe Plaque Psoriasis Involving the Hands and Feet with Raptiva®”** DermPA Today, Spring 2006; Vol 3, Number 1:4-5.
- Fretzin, S. **“Managing Cases of Chronic, Moderate-to-Severe Plaque Psoriasis Involving the Hands and Feet with Raptiva®”** DermNurse, Spring 2006; Vol 2, Number 1:3-4.
- Fretzin, S. **“Managing Cases of Chronic, Moderate-to-Severe Plaque Psoriasis Involving the Hands and Feet with Raptiva®”** Derm Resident, Spring 2006; Vol 5, Number 5:5-6.
- Fretzin S., Crowley, J., Jones, L., Young, M., Sobell, J. **“Successful Treatment of Hand And Foot Psoriasis with Efalizumab Therapy.”** Journal of Drugs in Dermatology. October 2006; Vol 5, Issue 9; 838-846.
- Fretzin S., Dawes K. *J Am Acad Dermatol* 2005; 52:P182. Abstract P2745.
- S. Fretzin. **“Answer All Your Patients’ Questions About STDs.”** Skin Aging 2000; 8 (8) :36-42.
- R. Huff, S. Fretzin, C. Lewis. **“Penile Eruption on a Diabetic Man.”** Arch Dermatol 1999; 135 :845.
- R Huff, S. Fretzin. **“Vesicular Eruption on the Chest and Back.”** Archives of Dermatology on the internet, 1998.

Scott A. Fretzin, MD

Articles and Publications – continued

- S. Fretzin. ***“Ringworm and Molluscum Contagiosum.”*** Indiana Amateur Wrestling News-1997. pg 8.
- M. Fretzin, S. Fretzin, D. Fretzin. ***“A Papulonecrotic Eruption in a Young Man.”*** Arch Dermatol 1997; 133:1453-1458.
- T. Eads, S. Fretzin, C. Lewis. ***“Pruritic, Painful Eruption.”*** Arch Dermatol 1998; 134:231-236
- S. Fretzin. ***“Introduction to the Terminology of Ethics.”*** Ethics Workbook for Dermatology Residency Directors. 1998.
- S. Fretzin, W. Beeson, W. Hanke. ***“Ignition Potential of the 585 nm Pulsed Dye Laser: Review of the Literature and Safety Recommendations.”*** Dermatol Surg 1996; 22 699-702.
- G. Westhoven, S. Fretzin, C. Lewis. ***“A Woman with Lung Cancer and Exfoliative Dermatitis.”*** Arch Dermatol 1997; 133: 499-504.
- D. Fretzin, J. Sloan, K. Beer, S. Fretzin. ***“Eccrine Syringofibroadenoma: A Clear Cell Variant.”*** Am.J. of Dermatopathology 1995;17 (6): 591-593
- S. Fretzin, B. Allen, A. Vane Daal, S. Elgin. ***“A Drosophila melanogaster H3.3 cDNA Encodes a Histone Variant Identical with the Vertebrate H3.3.”*** Gene. 107 (1991) 341-342.
- F. Booyse, R. Bruce, M. Grover, S. Fretzin, J. Karkov, H. Modi, L. Casey. ***“Rapid Release of Plasminogen Activators From Cultured Human Umbilical Vein Endothelial Cells.”*** Blood. 66#5 (1985).
- JC. Cather, C. Ryan, K. Meeuwis, AJ. Potts Bleakman, AN. Naegeli, E. Edson-Heredia, JL. Poon, C. Jones, AN. Wallace, L. Guenther, S. Fretzin. ***“Patients’ Perspective on the Impact of Genital Psoriasis: A Qualitative Study”***

Presentations/Posters

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients With Moderate to Severe Scalp Psoriasis: Time to Meaningful Improvement in Patient-Reported Outcomes in a Phase 3b/4 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study (PSORIATYK SCALP)
January 2025

The American Academy of Dermatology Meeting. Alexa B. Kimball, MD, MPH¹; Lindsay Ackerman, MD²; Bethanee J. Schlosser, MD, PhD³; Vimal H. Prajapati, MD⁴; Scott Fretzin, MD⁵; Hidetoshi Takahashi, MD⁶; Tianyu Zhan, PhD³; Xiaohong Huang, PhD³; Heidi S. Camp, PhD³ Efficacy and Safety of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Study.
March 2023

The American Academy of Dermatology Meeting. D. Rosmarin, S. Fretzin, L. Strowd, M. Casillas, A. DeLozier, Z. Dawson, S. Chen, N. Lu, J Thyssen. Rapid Improvement in Skin Pain and its Impact on Quality of Life in Adult Patients with Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study.
March 2021

Scott A. Fretzin, MD

Presentations/Posters – continued

The American Academy of Dermatology Meeting. A. Armstrong, K. Callis Duffin, A. Van Voorhees, A. Blauvelt, S. Fretzin, A. Jacobson. Improvements in Quality of Life by Categories of Skin Clearance in Clinical Trials of Brodalumab Through 52 Weeks. March 2020

Maui Derm for Dermatologist. 120-Week Efficacy. A. Blauvelt, S. Fretzin, M. Bettencourt, C. Leonardi, R. Pillai, A. Jacobson. Post Hoc Analysis of Long-term Efficacy and Safety of Brodalumab by Baseline Disease Severity. January, 2019

XXIV World Congress of the ISSVD. J. Clay Cather, A. Potts Bleakman, C Ryan, J. Ling Poon, B. Malatstinic, A. Naegeli, S. Fretzin. The Burden and Impact of Moderate-to-Severe Genital Psoriasis on Female Patients. September, 2017

The American Academy of Dermatology Meeting. C. Ryan, K. Meeuwis, A. Potts Bleakman, A. Naegeli, J. Ling Poon, K. Hollister, S. Fretzin. The Burden of Moderate-To-Severe Genital Psoriasis: Patients' Perspective on Symptoms. March, 2017

The American Academy of Dermatology Meeting. J. Clay Cather, A. Potts Bleakman, A. Naegeli, J. Ling Poon, A. Wallace, K. Hollister, S. Fretzin. Patients' Perspective on the Impact of Moderate-To-Severe Genital Psoriasis. March, 2017

The American Academy of Dermatology Meeting. N. Korman, H. Sofen, P. Rich, S. Fretzin, Y. Zhao, V. Herrera, M. Mordin, N. Williams, J. Nyirady, S. Tying. Secukinumab Provides More Effective Relief From Psoriasis Impact on Personal

Relationships and Influence on Clothes Worn Than Etanercept and Placebo. March, 2016

The American Academy of Dermatology Meeting. H. Sofen, N. Korman, P. Rich, S. Fretzin, Y. Zhao, V. Herrera, B. Sherif, L. McLeod, J. Nyirady, S. Tying. Secukinumab Provides More Effective Relief From Skin-Related Quality-of-Life Impact Than Placebo in Moderate to Severe Psoriasis. March, 2016

The American Academy of Dermatology Meeting. S. Tying, H. Sofen, S. Fretzin, P. Rich, Y. Zhao, V. Herrera, B. Sherif, N. Williams, J. Nyirady, N. Korman. Secukinumab Provides More Effective Relief From Skin-Related Quality-of-Life Impact Than Etanercept in Moderate to Severe Psoriasis. March, 2016

The American Academy of Dermatology Meeting. A. Armstrong, S. Fretzin, S. McBride, R. Burge, B. Zhu, E. Edson-Heredia, F. Zhao, A. Beselin, K. Gordon. Treatment with ixekizumab over 60 weeks provides sustained improvements in work productivity and activity levels: Results from UNCOVER-1, a Phase 3 trial in patients with moderate-to-severe psoriasis. March, 2016

The American College of Rheumatology Annual Meeting. M. Cesaroni, J. Jordan, J. Schreiter, M. Chevrier, G. Wang, C. Calderon, A. Piantone, I. Gourley, S. Cohen, S. Fretzin, A. Wonzniacka, VP. Werth, J. Benson. Identification of Molecular Biomarkers to Distinguish Systemic Lupus Erythematosus with Skin Involvement from Discoid Lupus Erythematosus and Subacute Cutaneous Erythematosus: Provisional Results from Cross-Sectional Studies [abstract]. *Arthritis Rheumatol*, 2015; 67 (suppl 10), November 6-11, 2015

Scott A. Fretzin, MD

Presentations/Posters – continued

The American Academy of Dermatology Meeting. S. Philipp, S. Fretzin, M. Notter, C. Papavassilis. Secukinumab Effect on Functional Ability in Subjects With Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: A Subanalysis From the FIXTURE Study. March, 2014

World Congress of Dermatology. C. Leonardi, J. Sobell, S. Fretzin, H. Sofen, T. Hamilton, Y. Chen, C. Ivor, A. Menter. Phase IV Study to Evaluate the Safety and Efficacy of Efalizumab in the Treatment of Hand and Foot Plaque Psoriasis. October, 2007

68th SID Annual Meeting. A. Ehrlich, S. Fretzin, W. Werther, Y. Chen, I. Caro, D. Pariser. Prevalence of Cardiovascular Risk Factors by Psoriasis Severity in Biologic-Treated Patients: The RESPONSE Cohorts. May 9-12, 2007.

Australasian College of Dermatologists 39th Annual Scientific Meeting. S. Fretzin, K. Dawes, AC Rundle, I Caro. Safety of a topically applied novel small molecule inhibitor of the Hedgehog signaling pathway in subjects with basal cell carcinoma. May 14-17, 2006.

The American Academy of Dermatology Meeting (64th Annual). J. Sobell, S. Fretzin. Case studies of efalizumab in hand and foot psoriasis. March 3-7, 2006.

The American Academy of Dermatology Meeting. S. Fretzin, A. Menter, R. Langley, D. Cohen. Therapeutic Strategies and Treatments for Psoriasis (CME/CD-ROM). February, 2005.

The American Academy of Dermatology Meeting. S. Fretzin, K. Dawes. Efficacy and Safety of Efalizumab for Patients with Palmoplantar Pustulosis. February, 2005.

The American Academy of Dermatology Meeting. S. Fretzin, J. Cotton, A. Hood. Aleukemic Lymphoblastic Leukemia Cutis in a 14 month-old girl. San Francisco, California. 1997.

The American Society for Dermatopathology Meeting. J. Cotton, S. Fretzin, A. Hood. Cutaneous Lymphoblastic Lymphoma in children. Two case reports and review of the literature. San Francisco, California. March, 1997.

The United States and Canadian Academy of Pathology Meeting. J. Cotton, S. Fretzin, R. Neiman. Cutaneous Lymphoblastic Lymphoma in children. Two case reports and review of the literature. Orlando, Florida. March 1997.

St. Vincent's Hospital Dermatopathology Conference. S. Fretzin. Degos' Syndrome. January 1997.

St. Vincent's Hospital Dermatopathology Conference. S. Fretzin. Well's Syndrome. September 1996.

The American Academy of Dermatopathology Meeting, 1996. S. Fretzin, H. Faust. Atypical Cutaneous reaction to Benazepril with histologic features of Mycosis Fungoides.

The American Society for Cell Biology Regional Meeting. Poster Presentation. S. Elgin, A. Van daal, S. Fretzin, E. White, M. Gorovsky. "Histone Variants H2Avd and H3.3 of *Drosophila melanogaster*." March, 1990.

UCLA Symposium on Transcriptional Control of Cell Growth. A. Van daal, S. Fretzin, E. White, M. Gorovsky, S. Elgin. "Histone Variants H1Avd and H3.3. of *Drosophila melanogaster*." January, 1990.

Scott A. Fretzin, MD

Other Research Experience

- 1988-90 Washington University of St. Louis, Dept. of Biology, Sarah C. Elgin, Ph.D.; Characterization of *Drosophila melanogaster* Histone Variant Gene.
- 1986-88 Barnes Hospital, Dept. of Dermatology, Eugene Bauer, M.D.; Collagenase assays for research in Epidermolysis Bullosa.
- 1987 Michael Reese Hospital, Dept. of Immunology, Enrique Beckman M.D.; Gene Rearrangement of Lymphomas.
- 1985-86 Michael Reese Hospital, Dept. of Immunology, Francoise Booyse, Ph.D.; Release of Plasminogen activators from human endothelial cells.

Clinical Studies conducted outside of Dawes Fretzin Clinical Research Group, LLC

Genital Warts

Sponsor: 3M

Safety and efficacy trial evaluation 5% Imiquimod Cream application to external genital warts and an extended treatment area; 1999-02

Diabetes

Sponsor: Takeda

Acting Agent: Quintiles, Inc.

An open-label, long-term extension study of voglibose (AO_128) in Type II Diabetes Mellitus patients; March 1997 to June 1999

Atopic Dermatitis

Sponsor: Connetics Therapeutics

An open-label, follow-on study of the safety and efficacy of Recombinant Interferon- γ 1b in subjects with moderate to severe atopic Dermatitis; September 1996 to December 1998

Atopic Dermatitis

Sponsor: Connetics Therapeutics

A Phase III study of the safety and efficacy of Recombinant Interferon- γ 1b in subjects with moderate to severe atopic Dermatitis; September 1996 to April 1998

Diabetes

Sponsor: Takeda

Acting Agent: Covance, Inc

A double-Blind, Placebo-Controlled, Randomized, Dose-Titration Study to Evaluate the Safety and Efficacy of Pioglitazone; January 1997 to December 1998

Scalp Psoriasis

Sponsor: Connetics Therapeutics

A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Betamethasone Valerate Foam in Treating Scalp Psoriasis; April 1997 to December 1997

Scott A. Fretzin, MD

Clinical Studies conducted outside of Dawes Fretzin Clinical Research Group, LLC - continued

Bronchitis

Sponsor: Bristol-Myers Squibb

A Double-blind Multicenter Comparative Study of Cefprozil (250mg bid) versus Cefuroxime Axetil (250mg bid) in the Treatment of Bronchitis; *December 1995 to April 1997*

Non-Insulin Dependent Diabetes Mellitus

Sponsor: Parke Davis

A 20-week, Double-Blind, Randomized Study of Troglitazone (CL-991) in patients with Non-Insulin Dependent Diabetes Mellitus; *June 1995 to May 1997*

Diabetes

Sponsor: Takeda

Acting Agent: Quintiles, Inc

A Randomized, Double-Blind, Placebo-Controlled, Six-Month, Safety and Efficacy Trial of 0.1, 0.5, 1, 2, 5 mg TID of Voglibose (AO-128) in Type II Diabetes Mellitus Patients; *October 1996 to December 1997*

Osteoarthritis

Sponsor: Merck

A Double-Blind, Randomized, Multicenter Study to Compare the Safety of Dexibuprofen Lysine with Ibuprofen for Long-Term Treatment of Osteoarthritis; *September 1996 to June 1997*

Rheumatoid Arthritis

Sponsor: Boston Life Sciences, Inc

A Double-Blind, Randomized Study of Therafectin 6 grams/day compared to Placebo in Patients with Rheumatoid Arthritis Withdrawn from their Nonsteroidal Anti-Inflammatory Drug Therapy; *June 1996 to July 1997*

Psoriasis

Sponsor: Seragen, Inc

Phase II Randomized, Double-Blind, Placebo-Controlled Trial of DAB389IL-2 in Patients with Moderate to Severe Plaque-Type Psoriasis; *June 1995 to October 1996*

Xerostomia and Keratoconjunctivitis Sicca

Sponsor: Snowbrand Milk Products, *Acting Agent:* Pharmaco LSR

A pilot study of SNI-2011 in patients with Sjogren's Syndrome experiencing xerostomia and keratoconjunctivitis Sicca; *July 1995 to December 1996*

Intermittent Claudication

Sponsor: Marion Merrell Dow

Dose-Response Evaluation of Beraprost Sodium IR Tablets in Treatment of Intermittent Claudication; *October 1995 to December 1996*

Scott A. Fretzin, MD

Clinical Studies conducted at Dawes Fretzin Clinical Research Group, LLC

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Bausch Health	V01-121A-302	Acne	PI	3	01-Mar-21
Cipher Pharma	ISOCT.08.01	Acne	PI	3	18-Oct-11
Cipher Pharma	RAN.13.01	Acne	PI	3	13-Mar-14
Dow Pharma Sciences	DPSI-IDP-107-P2-02	Acne	PI	2	14-Jun-11
Foamix	FX2014-05	Acne	PI	3	27-Apr-17
Novum	70608502	Acne	PI	2	03-Sep-08
Stiefel	W0261-301	Acne	PI	3	22-Oct-09
UPENN	Acne	Acne	PI	4	16-Apr-25
Valeant	V01-121A-302	Acne	PI	3	09-May-17
Allergan	225678-007	Acne	Sub-I	3	21-Jan-15
Bausch Health	V01-121A-501	Acne	Sub-I	1b	01-Oct-19
Dr. Reddy's	DFD-03-CD-006	Acne	Sub-I	2	31-Jul-18
Elorac	EL-1006-01-01	Acne	Sub-I	2	06-Jun-17
Foamix	FX2017-22	Acne	Sub-I	2	28-Sep-18
Galderma	RD.06.SPR.18088	Acne	Sub-I	3	22-Jan-08
Johnson & Johnson	732-ACN-2035	Acne	Sub-I	4	01-Jun-07
Ranbaxy	ABS1517LT	Acne	Sub-I	4	24-Apr-18
Sanofi	VBE00001	Acne	Sub-I	1/2	24-Feb-26
Stiefel	W0260-301	Acne	Sub-I	3	18-Jan-11
Taro	CLBG1210	Acne	Sub-I	3	04-Feb-14
Valeant	V01-123A-501	Acne	Sub-I	1b	14-Mar-17
Warner Chilcott	PR-10411	Acne	Sub-I	2	09-Jan-13
Aczone	225678-007	Acne	Sub-I	3	01-Mar-16
3M Pharmaceuticals	1502-IMIQ	Actinic Keratosis	PI	3b	04-Aug-05
3M Pharmaceuticals	1502-IMIQ-13	Actinic Keratosis	PI	3b	06-Jun-07
Athenex	KX01-AK-004	Actinic Keratosis	PI	3	21-Nov-19
3M Pharmaceuticals	1502-IMIQ	Actinic Keratosis	Sub-I	3b	04-Aug-05
Actavis	094-3153-301	Actinic Keratosis	Sub-I	4	11-Jun-14
Actavis	094-8151-301	Actinic Keratosis	Sub-I	4	17-Dec-15
Actavis	094-8152-301	Actinic Keratosis	Sub-I	4	22-May-17
LEO	LP0084-1148	Actinic Keratosis	Sub-I	2	15-Sep-15
LEO	LP0105-1012	Actinic Keratosis	Sub-I	1/2	13-Aug-14
LEO	LP0105-1032	Actinic Keratosis	Sub-I	3	13-Oct-17
Peplin	PEP005-016	Actinic Keratosis	Sub-I	3b	07-Jan-10
Peplin	PEP005-020	Actinic Keratosis	Sub-I	3b	26-Mar-10
Peplin	PEP005-028	Actinic Keratosis	Sub-I	3b	21-Jan-10
Peplin	PEP005-030	Actinic Keratosis	Sub-I	3b	11-Jan-11
Peplin	PEP005-032	Actinic Keratosis	Sub-I	3b	11-Jan-11
Perrigo	PRG-NY-14-019	Actinic Keratosis	Sub-I	3	14-Dec-15
Merck	A-11107	Allergen Immunotherapy	Sub-I	OBS	09-Apr-13
Abbvie	M24-725	Alopecia Areata	PI	3	ONGOING
CorEvitas	AA-565	Alopecia Areata	PI	OBS	ONGOING

Scott A. Fretzin, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Lilly	I4V-MC-JAIR	Alopecia Areata	PI	3	13-Mar-25
Pfizer	B7931005	Alopecia Areata	PI	2a	12-Mar-19
Pfizer	B7981015	Alopecia Areata	PI	2b/3	03-Aug-21
Pfizer	B7981027	Alopecia Areata	PI	3	ONGOING
Pfizer	B7981028	Alopecia Areata	PI	3	ONGOING
Pfizer	B7981031	Alopecia Areata	PI	1	17-Oct-23
Pfizer	B7981032	Alopecia Areata	PI	3	01-Aug-24
Pfizer	B7981094	Alopecia Areata	PI	3	ONGOING
Pfizer	B7981110	Alopecia Areata	PI	3	ONGOING
Reistone	RSJ10521	Alopecia Areata	PI	2	26-Aug-21
Adelphi	AG9909	Alopecia Areata	Sub-I	OBS	15-Apr-26
AnaptysBio	ANB030-201	Alopecia Areata	Sub-I	2	22-Mar-23
Arena	APD334-205	Alopecia Areata	Sub-I	2	30-Aug-23
Aslan	ASLAN003-004	Alopecia Areata	Sub-I	2a	12-Aug-24
Concert	CP543.3001	Alopecia Areata	Sub-I	3	13-Jul-23
Concert	CP543.5001	Alopecia Areata	Sub-I	3	28-Apr-26
DrenBio	DR-01-AIM-001	Alopecia Areata	Sub-I	1b	ONGOING
DRG Abacus	7785	Alopecia Areata	Sub-I	OBS	01-Sep-19
Evidera	EVA-20417-00	Alopecia Areata	Sub-I	OBS	11-Mar-20
HCW Biologics	HCWALO101	Alopecia Areata	Sub-I	1b	ONGOING
Horizon	HZNP-DAX-201	Alopecia Areata	Sub-I	2a	28-Mar-23
Inmagene	IMG-007-002	Alopecia Areata	Sub-I	1b/2a	28-Jun-24
Lilly	I4V-MC-JAIO	Alopecia Areata	Sub-I	3	ONGOING
Sanofi	DRI18180	Alopecia Areata	Sub-I	2	10-Feb-25
Sun Pharma	CP543.3101	Alopecia Areata	Sub-I	3	ONGOING
Pelage	PP405-2001	Androgenetic Alopecia	Sub-I	2a	24-Nov-25
Pelage	PP405-2002	Androgenetic Alopecia	Sub-I	2/3	ONGOING
Veradermics	250-13951-302	Androgenetic Alopecia	Sub-I	3	ONGOING
Veradermics	250-13951-306	Androgenetic Alopecia	Sub-I	3	ONGOING
GSK	SAS115358	Asthma	Sub-I	4	30-Oct-13
GSK	SAS115359	Asthma	Sub-I	4	01-May-14
Abbvie	M16-045	Atopic Dermatitis	PI	3	04-Feb-26
Abbvie	M16-046	Atopic Dermatitis	PI	3b	01-Feb-21
Abbvie	M16-047	Atopic Dermatitis	PI	3	ONGOING
Abbvie	M16-049	Atopic Dermatitis	PI	2b	29-Oct-24
Abbvie	M17-380	Atopic Dermatitis	PI	3	ONGOING
Abbvie	M19-850	Atopic Dermatitis	PI	3b	21-Apr-22
Abbvie	M23-696	Atopic Dermatitis	PI	3b/4	29-Oct-24
Abbvie	M24-601	Atopic Dermatitis	PI	3b/4	12-Jun-25
Aclaris	ATI-045-AD-201	Atopic Dermatitis	PI	2b	ONGOING
Amgen	20210144	Atopic Dermatitis	PI	3	29-Apr-25
Amgen	20210145	Atopic Dermatitis	PI	3	26-Feb-26
Amgen	20210146	Atopic Dermatitis	PI	3	ONGOING
Anacor	AN2728-AD-203	Atopic Dermatitis	PI	2a	21-Jan-13

Scott A. Fretzin, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Anacor	AN2728-AD-301-302-POST01	Atopic Dermatitis	PI	OBS	ONGOING
Anacor	AN2728-AD-302	Atopic Dermatitis	PI	3	11-Aug-15
Anacor	AN2728-AD-303	Atopic Dermatitis	PI	3	11-Nov-15
Apogee	APG777-301	Atopic Dermatitis	PI	3	ONGOING
Apollo	AP43CP03	Atopic Dermatitis	PI	2	04-Nov-25
Apollo	AP43CP04	Atopic Dermatitis	PI	2b	ONGOING
Aslan	ASLAN004-003	Atopic Dermatitis	PI	2b	04-Jan-24
Biosion	BSI-045B-002	Atopic Dermatitis	PI	2a	18-Jul-24
Cara	CR845-310501	Atopic Dermatitis	PI	3	07-Mar-24
CastleBio Science	CBI_2021_ISD_DevVal_001	Atopic Dermatitis	PI	4	02-Dec-25
Chugai	CIM003JG	Atopic Dermatitis	PI	2	20-Oct-16
Connect	CBP-201-WW004	Atopic Dermatitis	PI	3	30-Dec-22
CorEvitas	AD-550	Atopic Dermatitis	PI	4	ONGOING
Corrona	Corrona-AD-550	Atopic Dermatitis	PI	4	ONGOING
Dermavant	RVT-502-2001	Atopic Dermatitis	PI	2	01-Aug-18
Dermira	DRM06-AD01	Atopic Dermatitis	PI	2b	30-Jul-19
Dermira	DRM06-AD07	Atopic Dermatitis	PI	3	09-Apr-25
Dermira	DRM06-AD17	Atopic Dermatitis	PI	3	24-Aug-22
Galderma	RD.06.SPR.118126	Atopic Dermatitis	PI	2	11-Jun-25
Galderma	RD.06.SPR.118161	Atopic Dermatitis	PI	3	13-Feb-23
Galderma	RD.06.SPR.118163	Atopic Dermatitis	PI	3	20-Jan-26
Galderma	RD.06.SPR.118380	Atopic Dermatitis	PI	2	21-Dec-23
Galderma	SPR207806	Atopic Dermatitis	PI	OBS	ONGOING
Genentech	ACD3331g	Atopic Dermatitis	PI	2	06-Oct-05
GSK	203121	Atopic Dermatitis	PI	2	29-Mar-17
GSK	205050	Atopic Dermatitis	PI	2a	11-Jan-18
Incyte	INCB18424-303	Atopic Dermatitis	PI	3	28-Jan-21
Incyte	INCB18424-305	Atopic Dermatitis	PI	3	26-Jun-24
Incyte	INCB18424-902	Atopic Dermatitis	PI	4	05-Feb-25
Janssen	95475939ADM2001	Atopic Dermatitis	PI	2b	12-May-26
Janssen	95597528ADM2001	Atopic Dermatitis	PI	2b	ONGOING
Kymab	KY1005-CT05	Atopic Dermatitis	PI	2b	02-May-24
Kyowa Hakko Kirin	4083-006	Atopic Dermatitis	PI	2	15-Sep-20
LEO	LP0133-1181	Atopic Dermatitis	PI	1	25-Jun-20
Lilly	F1P-MC-KFAD	Atopic Dermatitis	PI	1	21-Jun-22
Lilly	I4V-MC-JAHL	Atopic Dermatitis	PI	3	06-Dec-18
Lilly	I4V-MC-JAHN	Atopic Dermatitis	PI	3	21-Sep-20
Lilly	I4V-MC-JAIW	Atopic Dermatitis	PI	3	03-Aug-20
Lilly	I4V-MC-JAIX	Atopic Dermatitis	PI	3	03-Aug-20
Lilly	J2T-MC-KGBO	Atopic Dermatitis	PI	3b	01-Apr-25
Lilly	J2T-MC-KGCE	Atopic Dermatitis	PI	4	ONGOING
MedImmune	D5240C00001	Atopic Dermatitis	PI	2a	22-Sep-16
Novan	NI-AD101	Atopic Dermatitis	PI	1b	25-Jun-18
Novartis	CBPR277X2101	Atopic Dermatitis	PI	1	13-Feb-13

Scott A. Fretzin, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
OM1	DataDerm	Atopic Dermatitis	PI	OBS	19-Aug-23
Pfizer	B7451006	Atopic Dermatitis	PI	2b	26-Apr-17
Pfizer	B7451012	Atopic Dermatitis	PI	3	23-May-19
Pfizer	B7451013	Atopic Dermatitis	PI	3	27-Jun-19
Pfizer	B7451014	Atopic Dermatitis	PI	3	19-Nov-20
Pfizer	B7451015	Atopic Dermatitis	PI	3	25-Mar-25
Pfizer	B7451023	Atopic Dermatitis	PI	3	ONGOING
Pfizer	B7451031	Atopic Dermatitis	PI	3	ONGOING
Pfizer	B7451036	Atopic Dermatitis	PI	3	21-May-20
Pfizer	B7451050	Atopic Dermatitis	PI	3b	12-Aug-21
Pfizer	C0341001	Atopic Dermatitis	PI	1	09-Oct-18
Pfizer	C3941002	Atopic Dermatitis	PI	2a	15-Nov-21
Pfizer	C3941005	Atopic Dermatitis	PI	2b	01-Aug-23
Pfizer	C4531002	Atopic Dermatitis	PI	2	ONGOING
Pfizer	C4531005	Atopic Dermatitis	PI	3	ONGOING
Quient	Q301-AD-P2-US002	Atopic Dermatitis	PI	2	07-Jan-20
Regeneron	R668-AD-1225	Atopic Dermatitis	PI	3	27-Sep-17
Regeneron	R668-AD-1314	Atopic Dermatitis	PI	2	10-Dec-15
Regeneron	R668-AD-1334	Atopic Dermatitis	PI	3	31-May-16
Regeneron	R668-AD-1415	Atopic Dermatitis	PI	3	08-Feb-17
Regeneron	R668-AD-1434	Atopic Dermatitis	PI	3	09-Dec-20
Regeneron	R668-AD-1526	Atopic Dermatitis	PI	3	19-Jul-18
Regeneron	R668-AD-1607	Atopic Dermatitis	PI	1b	10-Apr-18
Roche	CS45570	Atopic Dermatitis	PI	2	ONGOING
Roche	CS45943	Atopic Dermatitis	PI	2	N/A
Sanofi	EFC17561	Atopic Dermatitis	PI	3	03-Feb-26
Sanofi	EFC17599	Atopic Dermatitis	PI	3	ONGOING
Sanofi	EFC17600	Atopic Dermatitis	PI	3	ONGOING
Sanofi	LPS15496	Atopic Dermatitis	PI	OBS	27-Apr-21
Sanofi	LTS17367	Atopic Dermatitis	PI	2/3	ONGOING
Sanofi	OBS15333	Atopic Dermatitis	PI	OBS	27-Apr-21
Sun Pharmaceuticals	71542612	Atopic Dermatitis	PI	3	15-Feb-18
Taro	RXLC-2118	Atopic Dermatitis	PI	4	04-Dec-24
TrialSpark	ASN008-201	Atopic Dermatitis	PI	2	14-Feb-24
Aclaris	ATI-1777-AD-201	Atopic Dermatitis	Sub-I	2a	23-Jun-21
Aclaris	ATI-1777-AD-202	Atopic Dermatitis	Sub-I	2b	06-Feb-24
Acrotech	MEDI-MM36-301	Atopic Dermatitis	Sub-I	3	20-Nov-23
Acrotech	MEDI-MM36-302	Atopic Dermatitis	Sub-I	3	16-Jul-24
Alumis	ESK-001-006	Atopic Dermatitis	Sub-I	2	08-Sep-23
Alumis	ESK-001-007	Atopic Dermatitis	Sub-I	2	13-Feb-24
Arcutis	ARQ-151-212	Atopic Dermatitis	Sub-I	2	10-Dec-19
Arcutis	ARQ-151-313	Atopic Dermatitis	Sub-I	3	11-Jul-23
Asana	ASN002AD-201	Atopic Dermatitis	Sub-I	2b	25-Sep-19
Asana	ASN002AD-201-EXT	Atopic Dermatitis	Sub-I	2	10-Mar-20

Scott A. Fretzin, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Astellas	FHI-03-0-161/FG-506-06-37	Atopic Dermatitis	Sub-I	2	01-Oct-12
Attovia	ATTO-3712-101	Atopic Dermatitis	Sub-I	1	ONGOING
BMS	IM011-005	Atopic Dermatitis	Sub-I	2	01-Aug-22
BMS	IM018-005	Atopic Dermatitis	Sub-I	2	20-Sep-22
BMX	BMX-DERM-01	Atopic Dermatitis	Sub-I	1/2	24-Aug-21
Celgene	CC-93538-AD-001	Atopic Dermatitis	Sub-I	2	07-Dec-22
Ceragenix	CPI-2006-002	Atopic Dermatitis	Sub-I	2	23-Apr-07
Dermavant	RVT-501-2007	Atopic Dermatitis	Sub-I	1b	03-Aug-18
DermTech	20-03	Atopic Dermatitis	Sub-I	4	24-Oct-23
Enveda	ENV-294-202	Atopic Dermatitis	Sub-I	2b	ONGOING
Evidera	EVA-25835	Atopic Dermatitis	Sub-I	OBS	15-Dec-23
Evommune	EVO101-AD001	Atopic Dermatitis	Sub-I	2a	29-Aug-23
Galapagos	MOR106-CL-204	Atopic Dermatitis	Sub-I	2	28-Oct-19
GSK	201551	Atopic Dermatitis	Sub-I	3	07-Jul-05
GSK	215253	Atopic Dermatitis	Sub-I	1b	13-Jun-23
Incyte	INCB18424-206	Atopic Dermatitis	Sub-I	2	18-May-18
Janssen	77474462ADM2001	Atopic Dermatitis	Sub-I	3	16-May-22
Janssen	77474462ADM2003	Atopic Dermatitis	Sub-I	2a	06-Apr-22
Kiniksa	KPL-716-C001	Atopic Dermatitis	Sub-I	1b	20-Sep-19
LEO	LP0145-2240	Atopic Dermatitis	Sub-I	2b	25-Jun-25
LEO	LP0162-1326	Atopic Dermatitis	Sub-I	3	15-Oct-19
LEO	LP0162-1337	Atopic Dermatitis	Sub-I	3	27-Jan-23
LEO (Apple)	LP0156-1294	Atopic Dermatitis	Sub-I	OBS	24-Oct-17
Lilly	J2T-MC-B002	Atopic Dermatitis	Sub-I	4	ONGOING
Lilly	J2T-MC-KGBP	Atopic Dermatitis	Sub-I	3b	02-Apr-25
Organon	OG0505-3104	Atopic Dermatitis	Sub-I	3	ONGOING
Ralexar	ALX-101-ATOP-204	Atopic Dermatitis	Sub-I	2	27-Jan-20
Rapt	RPT193-01	Atopic Dermatitis	Sub-I	1	26-Jul-21
Rapt	RPT193-02	Atopic Dermatitis	Sub-I	2	07-Jun-24
TARGET-DERM	TARGET-DERM	Atopic Dermatitis	Sub-I	4	06-Apr-26
Taro (CRO Novum)	TACR-0707	Atopic Dermatitis	Sub-I	2	12-May-09
Triveni Bio	TRIV-509-101	Atopic Dermatitis	Sub-I	2a	ONGOING
Triveni Bio	TRIV-573-101	Atopic Dermatitis	Sub-I	2	ONGOING
Xbiotech	2019-PT046	Atopic Dermatitis	Sub-I	2	21-Feb-21
Brickell	BBI-4000-CL-301	Axillary Hyperhidrosis	Sub-I	3	11-Aug-21
Genentech	THA3435g	Basal Cell Carcinoma	PI	1	27-Jul-06
CoPharma	PEN-203	Basal Cell Carcinoma	Sub-I	1/2	01-Dec-00
Akari	AK802	Bullous Pemphigoid	PI	3	08-Sep-22
AstraZeneca	D325AC00002	Bullous Pemphigoid	PI	3	31-Aug-23
Arcutis	ARQ-252-205	Chronic Hand Eczema	Sub-I	1/2b	07-Aug-20
Asana	ASN002AD-202	Chronic Hand Eczema	Sub-I	2	22-Jun-20
Celldex	CDX0159-07	Chronic Inducible Urticaria	Sub-I	2	25-Nov-25
Evommune	EVO756-CIU001	Chronic Inducible Urticaria	Sub-I	2a	20-Jun-25
Galderma	SPR207913	Chronic Pruritus of Unknown Origin	PI	2	ONGOING

Scott A. Fretzin, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Menlo	MTI-117	Chronic Pruritus of Unknown Origin	Sub-I	2	29-May-20
Novartis	CLOU064R12301	Chronic Pruritus of Unknown Origin	Sub-I	3	ONGOING
Sanofi	EFC16973	Chronic Pruritus of Unknown Origin	Sub-I	3	13-Nov-24
Amgen	20190194	Chronic Spontaneous Urticaria	PI	2b	20-Apr-23
Evidera	EVA-32391-01	Chronic Spontaneous Urticaria	PI	OBS	13-Mar-23
InflaRX	INF904-P2.1	Chronic Spontaneous Urticaria	PI	2a	04-Dec-25
Jasper Therapeutics	JSP-CP-011	Chronic Spontaneous Urticaria	PI	2a	ONGOING
Jasper Therapeutics	JSP-CP-014	Chronic Spontaneous Urticaria	PI	2	ONGOING
Novartis	CLOU064AUS04	Chronic Spontaneous Urticaria	PI	OBS	ONGOING
Blueprint Medicines	BLU-808-1201	Chronic Spontaneous Urticaria	Sub-I	2	ONGOING
Celldex	CDX0159-02	Chronic Spontaneous Urticaria	Sub-I	1	10-Jan-23
Celldex	CDX0159-06	Chronic Spontaneous Urticaria	Sub-I	2	07-Nov-23
Celldex	CDX0159-12	Chronic Spontaneous Urticaria	Sub-I	3	ONGOING
Celldex	CDX0159-17	Chronic Spontaneous Urticaria	Sub-I	3b	ONGOING
Escient	EP-262-201	Chronic Spontaneous Urticaria	Sub-I	2	26-Mar-25
Genentech	ACD4577g	Chronic Spontaneous Urticaria	Sub-I	2	10-Dec-09
Genentech	ML29510	Chronic Spontaneous Urticaria	Sub-I	4	27-Jun-17
Genentech	Q4882g	Chronic Spontaneous Urticaria	Sub-I	3	12-Sep-12
Novartis	CQGE031C2302	Chronic Spontaneous Urticaria	Sub-I	3	30-Sep-22
Novartis	CQGE031C2302E1	Chronic Spontaneous Urticaria	Sub-I	3b	25-Oct-22
Novartis	CQGE031C2201	Chronic Spontaneous Urticaria	Sub-I	2b	29-Jun-16
GSK	HZA106837	COPD	PI	3a	22-Nov-11
Forest	LAS-MD-38	COPD	Sub-I	3b	23-Nov-10
GSK	CTT116855	COPD	Sub-I	3	16-Jun-15
Novartis	CQAB149B2335S	COPD	Sub-I	3	16-Jan-09
Novartis	CQAB149B2341	COPD	Sub-I	3	16-Dec-10
Novartis	CQAB149B2346	COPD	Sub-I	3	16-Dec-08
Novartis	CQVA149A2336	COPD	Sub-I	3	07-May-14
GSK	LPL100601	Coronary Heart Disease	Sub-I	3	13-Aug-13
Biogen	230LE201	Cutaneous Lupus Erythematosus	PI	2	22-Jul-20
Biogen	230LE301	Cutaneous Lupus Erythematosus	PI	3	31-Oct-23
Biogen	230LE305	Cutaneous Lupus Erythematosus	PI	3	31-Oct-23
Celgene	CC-11050-CLE-002	Cutaneous Lupus Erythematosus	PI	2	01-Dec-12
Gilead	GS-US-497-5888	Cutaneous Lupus Erythematosus	PI	1b	29-Nov-22
Gilead	GS-US-497-6486	Cutaneous Lupus Erythematosus	PI	2a	19-May-26
Janssen	NOCOMPOUNDLUN0001	Cutaneous Lupus Erythematosus	PI	OBS	29-Oct-14
Merck	MS200569-0003	Cutaneous Lupus Erythematosus	PI	2	16-Jan-25
Merck	MS200569-0048	Cutaneous Lupus Erythematosus	PI	1	28-Jan-26
Merck	MS504908_0008	Cutaneous Lupus Erythematosus	PI	3	ONGOING
Pfizer	A6261008	Cutaneous Lupus Erythematosus	PI	3	26-Feb-14
Ventus	VENT-03-201	Cutaneous Lupus Erythematosus	PI	2a	ONGOING
Horizon	HZNP-DAX-202	Cutaneous Lupus Erythematosus	PI	2	21-Nov-25
Nflection	NFX-179-NFI-202	Cutaneous Neurofibroma	Sub-I	2	16-Oct-23
CastleBio Science	CBI_2019_cSCC_PVS_001	Cutaneous Squamous Cell Carcinoma	PI	4	ONGOING

Scott A. Fretzin, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Regeneron	R2810-ONC-2251	Cutaneous Squamous Cell Carcinoma	Sub-I	3	28-May-26
Elorac	EL-1007-01-01	Cutaneous T-Cell Lymphoma	Sub-I	3	20-Oct-22
Soligenix	HPN-CTCL-01	Cutaneous T-Cell Lymphoma	Sub-I	3	24-Feb-21
Soligenix	HPN-CTCL-03-EUR	Cutaneous T-Cell Lymphoma	Sub-I	3	ONGOING
Lilly	F3Z-US-IOOV	Diabetes - Type 2	Sub-I	3	01-Oct-08
Merck	079-00	Diabetes - Type 2	Sub-I	3	01-Oct-08
Takeda	TAK-875_306	Diabetes - Type 2	Sub-I	3	26-Feb-14
Lilly	I4K-MC-GPEC	Erectile Dysfunciton	PI	2	25-Jan-12
Lilly	H6D-MC-LVGO	Erectile Dysfunciton	Sub-I	3	21-Mar-06
Celgene	CC-10004-PSOR-025	Genital Psoriasis	PI	3	27-Apr-22
Evidera	EVA-16679	Genital Psoriasis	PI	OBS	01-Jun-15
Lilly	I1F-MC-RHBQ	Genital Psoriasis	PI	3	17-May-18
AnaptysBio	ANB019-002	GPP	PI	2a	20-Oct-20
AnaptysBio	ANB019-401	GPP/PPP	PI	3	02-Mar-23
Lilly	J2T-MC-KGCD	Hand/Foot Dermatitis	PI	3b	ONGOING
Regeneron	R668-AD-1924	Hand/Foot Dermatitis	Sub-I	3	22-Feb-23
Lilly	I4J-MC-HHBA	Healthy Volunteers - Biomarkers	PI	N/A	01-Jun-10
Pfarming	C1 1205-01	Hereditary Angioedema	PI	2	07-May-10
Inhbitex	INH-FV1-005	Herpes Zoster	Sub-I	2	10-Dec-10
Abbvie	M20-040	Hidradenitis Suppurativa	PI	2	15-Mar-22
Abbvie	M20-262	Hidradenitis Suppurativa	PI	2	ONGOING
Abbvie	M20-465	Hidradenitis Suppurativa	PI	3	ONGOING
Abbvie	M23-698	Hidradenitis Suppurativa	PI	3	ONGOING
Acelyrin	21102	Hidradenitis Suppurativa	PI	2	16-Apr-24
Acelyrin	22107	Hidradenitis Suppurativa	PI	3	26-Feb-25
Adelphi	AB6762B	Hidradenitis Suppurativa	PI	OBS	01-Mar-25
Boehringer Ingelheim	1368-0052	Hidradenitis Suppurativa	PI	2a	29-Mar-22
Boehringer Ingelheim	1368-0067	Hidradenitis Suppurativa	PI	2	31-Jan-23
Boehringer Ingelheim	1368-0098	Hidradenitis Suppurativa	PI	2b/3	31-Jul-25
Lilly	I7P-MC-DSAF	Hidradenitis Suppurativa	PI	2b	ONGOING
Merck	MK7240-012	Hidradenitis Suppurativa	PI	2b	ONGOING
Pfizer	B7981119	Hidradenitis Suppurativa	PI	2	ONGOING
Pfizer	C2501007	Hidradenitis Suppurativa	PI	2a	15-Feb-22
Sanofi	ACT17841	Hidradenitis Suppurativa	PI	2	19-Feb-26
Abbvie	H13-147	Hidradenitis Suppurativa	Sub-I	OBS	25-Feb-20
AstraZenaca	D5440C00001	Hidradenitis Suppurativa	Sub-I	2a	10-Dec-14
ChemoCentryx	CL016_168	Hidradenitis Suppurativa	Sub-I	2	11-May-21
CSL Bering	CS1324-2001	Hidradenitis Suppurativa	Sub-I	2	10-May-14
Incyte	INCB054707-801	Hidradenitis Suppurativa	Sub-I	3b	ONGOING
Incyte	INCB54707-301	Hidradenitis Suppurativa	Sub-I	3	17-Feb-26
Incyte	INCB54707-302	Hidradenitis Suppurativa	Sub-I	3	23-Jan-26
Incyte	INCB54707-312	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Incyte	INCB54707-312	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Janssen	77474462HDS2001	Hidradenitis Suppurativa	Sub-I	2	10-Feb-23

Scott A. Fretzin, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Moonlake	M1095-HS-201	Hidradenitis Suppurativa	Sub-I	2	02-Oct-23
Moonlake	M1095-HS-301	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Moonlake	M1095-HS-303	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Moonlake	M1095-HS-304	Hidradenitis Suppurativa	Sub-I	3	21-May-26
Novartis	CAIN457M2301E1	Hidradenitis Suppurativa	Sub-I	3	26-Aug-25
Novartis	CAIN457M2302	Hidradenitis Suppurativa	Sub-I	2/3	31-Oct-22
Novartis	CCFZ533H12201BC	Hidradenitis Suppurativa	Sub-I	2	ONGOING
Novartis	CCJM112X2202	Hidradenitis Suppurativa	Sub-I	2	29-Mar-17
Novartis	CLOU064J12301	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Xbiotech	2019-PT047	Hidradenitis Suppurativa	Sub-I	2	21-Feb-21
Novartis	SPP100A-2409	Hypertension	Sub-I	2	21-Jun-10
Mayne	18-ICH-001	Lamellar Ichthyosis	Sub-I	2	17-Jan-22
Timber	TMB01-301/MUST	Lamellar Ichthyosis	Sub-I	3	03-Dec-24
Priovant	PVT-2201-304	Lichen Planopilaris	Sub-I	2/3	ONGOING
Incyte	INCB18424-216	Lichen Planus	PI	2	25-Apr-24
Novartis	CGIA362C12201	Lichen Planus	Sub-I	2	ONGOING
Lilly	I5V-MC-TSAT	Low Testosterone	PI	3	25-Jun-15
Evidera	146323-01	Lower Abdominal Fat	Sub-I	OBS	01-Nov-25
Evidera	152364-01	Lower Abdominal Fat	Sub-I	OBS	01-Jun-26
Evidera	EVA-36509-01	Lower Abdominal Fat	Sub-I	OBS	08-Nov-23
Evidera	EVA-36509-02	Lower Abdominal Fat	Sub-I	OBS	18-Jul-24
Evidera	EVA-36509-04	Lower Abdominal Fat	Sub-I	OBS	23-Jan-25
Evidera	EVA-36509-08	Lower Abdominal Fat	Sub-I	OBS	18-Sep-25
Novan	NI-MC201	Molluscum Contagiosum	PI	2	09-Jan-19
Novan	NI-MC301	Molluscum Contagiosum	PI	3	09-Jan-19
DermTech	17-06	Multi-Indication	Sub-I	4	17-Jun-24
Novartis	CFTY720DUS01	Multiple Sclerosis	Sub-I	4	25-Jul-12
Lilly	I1F-MC-B018	Nail Psoriasis	Sub-I	OBS	29-Jan-25
BioCryst	BCX17725-101	Netherton Syndrome	Sub-I	1	ONGOING
Quoin	CL-QRX003-001	Netherton Syndrome	Sub-I	2	08-Apr-26
Quoin	CL-QRX003-002	Netherton Syndrome	Sub-I	2	ONGOING
Quoin	CL-QRX003-004	Netherton Syndrome	Sub-I	3	ONGOING
Quoin	CL-QRX003-005	Netherton Syndrome	Sub-I	3	ONGOING
Quoin	CL-QRX003-006	Netherton Syndrome	Sub-I	3	ONGOING
Mindera	MND-24-MK-02	Normal Skin	PI	1	30-Sep-25
DermTech	21-02	Normal Skin	Sub-I	4	29-Jan-24
Cara	CR845-210601	Notalgia Parasthetica	PI	2	11-Aug-22
Cara	CR845-310601	Notalgia Parasthetica	PI	2-3	02-Jul-24
Evidera	EVA-27657	Notalgia Parasthetica	PI	OBS	18-Mar-21
Evidera	EVA-37056-00	Notalgia Parasthetica	PI	OBS	24-Apr-24
Clexio	CLE400-NP-201	Notalgia Parasthetica	Sub-I	2	24-Jan-25
Lilly	I1L-MC-GAEB	Obesity	PI	2	16-Jul-10
Hisamitsu	HTU-520-US01	Onychomycosis	Sub-I	2	01-May-13
XOMA	X052160	Osteoarthritis of the Hand	Sub-I	2	10-Apr-14

Scott A. Fretzin, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
XOMA	X052161	Osteoarthritis of the Hand	Sub-I	2	01-Jun-15
XOMA	X052162	Osteoarthritis of the Hand	Sub-I	2	10-Apr-14
Pfizer (Precision)	A3191172	Osteoarthritis/Rheumatoid Arthritis	Sub-I	4	19-Sep-16
Abbvie	M15-994	Palmoplantar Psoriasis	PI	3b	17-Jul-23
BMS	IM011-1112	Palmoplantar Psoriasis	PI	4	02-Jul-25
Novartis	CAIN457A2312	Palmoplantar Psoriasis	Sub-I	3b	03-Apr-17
AnaptysBio	ANB019-003	Palmoplantar Pustulosis	PI	2	09-Jun-21
Aristea	RIST4721-202	Palmoplantar Pustulosis	Sub-I	2	12-May-23
Aziltra	CTAR-403	Papulopustular Rosacea	PI	1b/2a	10-Jun-21
Cutanea	CLS001-CO-PR-001.01	Papulopustular Rosacea	PI	2	17-Apr-14
Dr. Reddy's	DFD-29-CD-004	Papulopustular Rosacea	Sub-I	3	24-Jul-23
Galderma	RD.06.SPR.18171	Papulopustular Rosacea	Sub-I	3	11-Sep-13
Evidera	EVA-20259	Pediatric Psoriasis	PI	OBS	01-Oct-18
Galderma	RD.06.SPR.203065	Prurigo Nodularis	PI	3	13-Jun-22
Galderma	SPR207807	Prurigo Nodularis	PI	OBS	ONGOING
Sanofi	EFC16459	Prurigo Nodularis	PI	3	25-May-22
Galderma	RD.06.SPR.202699	Prurigo Nodularis	Sub-I	3	13-Jun-22
Incyte	INCB18424-110	Prurigo Nodularis	Sub-I	1	09-May-25
InnoCare	ICP-CL-00609	Prurigo Nodularis	Sub-I	2	ONGOING
Sanofi	OBS17721	Prurigo Nodularis	Sub-I	4	ONGOING
Abbott	M03-656	Psoriasis	PI	3	18-Sep-06
Abbott	M03-658	Psoriasis	PI	3	15-Oct-09
Abbott	M05-736	Psoriasis	PI	2	07-Jul-08
Abbott	M06-890	Psoriasis	PI	3	29-Jul-09
Abbott	M10-016	Psoriasis	PI	3	06-Mar-12
Abbott	M10-114	Psoriasis	PI	3	15-Apr-09
Abbott	M10-238	Psoriasis	PI	3	09-Jul-09
Abbott (ESPRIT)	P10-023	Psoriasis	PI	OBS	28-Mar-23
Abbvie	M15-997	Psoriasis	PI	3	20-Mar-23
Abbvie	M18-816	Psoriasis	PI	2	20-Mar-23
Abbvie	M19-164	Psoriasis	PI	3b	29-Sep-22
Abbvie	M19-164 Companion	Psoriasis	PI	3b	29-Sep-22
Abbvie	M20-326	Psoriasis	PI	4	17-Jul-23
Abbvie	M24-541	Psoriasis	PI	4	02-Jun-26
Akros	AE451-G-18-004	Psoriasis	PI	2/3	12-May-20
Allergan	1957-201-001	Psoriasis	PI	2b	22-May-18
Amgen	20030190	Psoriasis	PI	4	04-May-05
Amgen	20070559	Psoriasis	PI	3	15-Mar-11
Amgen	20101177	Psoriasis	PI	4	18-Mar-16
Amgen	20120104	Psoriasis	PI	3	22-Dec-15
Amgen	20190232	Psoriasis	PI	3	08-Sep-22
Amgen	20200196	Psoriasis	PI	3	ONGOING
Amgen	HRA1603A (20130126)	Psoriasis	PI	OBS	11-Feb-16
Amgen	HRA1889A	Psoriasis	PI	OBS	20-Aug-14

Scott A. Fretzin, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Amgen (Observe)	20040210	Psoriasis	PI	OBS	19-Feb-13
Astellas	04-0-206	Psoriasis	PI	3	05-Apr-07
Baxalta	911401	Psoriasis	PI	3	24-Oct-17
Biocon	BIO-USTEKI-305	Psoriasis	PI	3	20-Dec-22
Biocon	BM12H-PSO-03-G-02	Psoriasis	PI	3	11-Jan-24
BMS	IM011-1128	Psoriasis	PI	3	ONGOING
BMS	IM011-1130	Psoriasis	PI	3b/4	ONGOING
Boehringer Ingelheim	1311.28	Psoriasis	PI	3	21-Nov-17
Boehringer Ingelheim	1407-0005	Psoriasis	PI	2	21-Oct-21
Boehringer Ingelheim	1407-0030	Psoriasis	PI	2	22-Jul-21
Celgene	CC-10004-PPSO-003	Psoriasis	PI	3	03-Aug-23
Celgene	CC-10004-PPSO-004	Psoriasis	PI	3b	24-Mar-26
Celgene	CC-10004-PSOR-005	Psoriasis	PI	2b	26-Jan-10
Celgene	CC-10004-PSOR-005E	Psoriasis	PI	2b	11-Aug-10
Celgene	CC-10004-PSOR-008	Psoriasis	PI	3	06-Oct-16
Celgene	CC-10004-PSOR-010	Psoriasis	PI	3b	15-Jul-15
Celgene	CC-10004-PSOR-022	Psoriasis	PI	3	22-Oct-20
Centocor	C0379T04	Psoriasis	PI	2	17-Jun-05
Centocor	C0743T08	Psoriasis	PI	3	27-Jul-11
Centocor	C0743T09	Psoriasis	PI	3	16-Dec-11
Centocor	C0743T12	Psoriasis	PI	3	26-Feb-09
CorEvitas	CorEvitas-PSO-505	Psoriasis	PI	OBS	ONGOING
Corrona	Corrona-PSO-550	Psoriasis	PI	4	ONGOING
Dermavant	DMVT-505-3001	Psoriasis	PI	3	22-Jul-20
Dermira	PS0003	Psoriasis	PI	3	13-Mar-19
DICE Therapeutics	DCE806201	Psoriasis	PI	2	28-Mar-24
Dr. Reddy's	PPC-06-CD-004	Psoriasis	PI	2	28-May-19
Evidera	EVA-18225	Psoriasis	PI	OBS	02-Jun-16
Evidera	EVA-18225-01	Psoriasis	PI	OBS	03-Aug-16
Galderma	RD.06.SPR.18104	Psoriasis	PI	4	25-Feb-16
Galderma	RD.06.SPR.18131	Psoriasis	PI	4	29-Aug-18
Genentech	ACD2600g	Psoriasis	PI	3	12-Jun-03
Genentech	ACD2601g	Psoriasis	PI	3	15-Jul-04
Genentech	ACD3101g	Psoriasis	PI	3b	07-Oct-09
Genentech	ACD3753g	Psoriasis	PI	4	04-Jan-07
Genentech	ACD4412n	Psoriasis	PI	4	20-Sep-09
Genzyme	HECTPS02507	Psoriasis	PI	2	13-May-09
GSK	200851	Psoriasis	PI	3	01-Dec-13
Janssen	38515168PSO2001	Psoriasis	PI	2	13-Jan-16
Janssen	CNT01959PSO2001	Psoriasis	PI	2	01-Nov-13
Janssen	CNT01959PSO3002	Psoriasis	PI	3	10-Sep-20
Janssen	CNT01959PSO3003	Psoriasis	PI	3	19-Jul-16
Janssen	77242113PSO2001	Psoriasis	PI	2b	28-Sep-22
Janssen	77242113PSO2002	Psoriasis	PI	2b	23-Jan-23

Scott A. Fretzin, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Janssen	77242113PSO3001	Psoriasis	PI	3	19-Mar-24
Janssen	77242113PSO3002	Psoriasis	PI	3	20-Feb-25
Janssen	77242113PSO3003	Psoriasis	PI	3	14-Jan-25
Janssen	CNT01959PSO3018	Psoriasis	PI	3b	10-Sep-25
Kadmon	KD025-211	Psoriasis	PI	2	07-Nov-19
Lilly	F1P-MC-KFAC	Psoriasis	PI	1	03-Nov-21
Lilly	I1F-MC-RHAG	Psoriasis	PI	2	02-Jun-10
Lilly	I1F-MC-RHAZ	Psoriasis	PI	3	23-Jan-19
Lilly	I1F-MC-RHBC	Psoriasis	PI	3	17-Dec-19
Lilly	I1F-MC-RHBL	Psoriasis	PI	3	03-Oct-13
Lilly	I1F-MC-RHBP	Psoriasis	PI	3	07-Jun-17
Lilly	I1F-MC-RHCR	Psoriasis	PI	4	23-Jul-20
Lilly	I1F-MC-RHDC	Psoriasis	PI	3b	ONGOING
Lilly	I1F-MC-RHDD	Psoriasis	PI	3b	ONGOING
Lilly	I1X-MC-BDAD	Psoriasis	PI	2	30-Jul-10
Lilly	I6T-MC-AMAH	Psoriasis	PI	3	28-Apr-22
Lilly	I6T-MC-AMAJ	Psoriasis	PI	3	22-Jul-20
Lilly	I6T-MC-AMBK	Psoriasis	PI	2/3	28-Jul-21
Lilly	I7P-MC-DSAB	Psoriasis	PI	1	29-Aug-19
Lilly	I7P-MC-DSAB	Psoriasis	PI	1	29-Aug-19
LITE	PCS-1608-35830	Psoriasis	PI	2/3	05-Jul-24
Maruho	M518101-US01	Psoriasis	PI	2b	07-Mar-12
Maruho	M518101-US02	Psoriasis	PI	3	11-Sep-15
Merck	MK3222-010	Psoriasis	PI	3	28-Jan-20
Mindera	MND-21-MKPs-02	Psoriasis	PI	4	28-May-24
Novartis	CAIN457A2223	Psoriasis	PI	2	08-May-15
Novartis	CAIN457A2302E1	Psoriasis	PI	3	18-Nov-17
Novartis	CAIN457A2303	Psoriasis	PI	3	04-Apr-17
Novartis	CAIN457A2304	Psoriasis	PI	3	25-Oct-17
Novartis	CAIN457A2304E1	Psoriasis	PI	3	25-Oct-17
Novartis	CAIN457A2317	Psoriasis	PI	3b	19-Nov-16
Novartis	CAIN457A2324	Psoriasis	PI	3b	10-Nov-20
Novo-Nordisk	NN8226-1848	Psoriasis	PI	1/2a	03-Mar-11
Pfizer	B7451005	Psoriasis	PI	2	02-Sep-15
Pfizer	B7931004	Psoriasis	PI	2a	08-May-18
Pfizer	B7931004	Psoriasis	PI	2a	08-May-18
PSOLAR	C0168Z03	Psoriasis	PI	OBS	18-May-23
Sandoz	GP17-301	Psoriasis	PI	3	24-Jul-16
Sanofi	DRI17849	Psoriasis	PI	2	03-Dec-24
Sun Pharmaceuticals	71542611 (CRO NOVUM)	Psoriasis	PI	3	16-Feb-18
Tolmar	TOL2707A	Psoriasis	PI	3	02-Jun-16
UCB	PS0003	Psoriasis	PI	3	01-Apr-18
UCB	PS0010	Psoriasis	PI	2b	12-Jun-17
UCB	PS0020	Psoriasis	PI	2	17-Jul-24

Scott A. Fretzin, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
UCB	PS0021	Psoriasis	PI	3	ONGOING
UPENN	CP3	Psoriasis	PI	4	ONGOING
Ventyx	VTX958-201	Psoriasis	PI	2	13-Feb-24
Wyeth	3199K2-1105-US	Psoriasis	PI	1	06-Dec-10
Wyeth	3226K1-1002-VW	Psoriasis	PI	1	19-Sep-11
Abbott (ESPRIT)	P10-023	Psoriasis	Sub-I	OBS	28-Mar-23
Alumis	ESK-001-016	Psoriasis	Sub-I	3	17-Feb-26
Alumis	ESK-001-018	Psoriasis	Sub-I	3	ONGOING
Amgen	20030190	Psoriasis	Sub-I	4	04-May-05
Amgen	20120363	Psoriasis	Sub-I	OBS	12-Apr-17
Amgen (Observe)	20040210	Psoriasis	Sub-I	OBS	19-Feb-13
Arcutis	ARQ-151-302	Psoriasis	Sub-I	3	31-Mar-21
Arcutis	ARQ-151-306	Psoriasis	Sub-I	3	28-Apr-21
Arcutis	ARQ-151-311	Psoriasis	Sub-I	3	08-Nov-22
Arcutis	ARQ-154-204	Psoriasis	Sub-I	2b	02-Dec-20
Aurigene	AUR101-202	Psoriasis	Sub-I	2	12-Oct-22
BMS	IM011-011	Psoriasis	Sub-I	2	23-Aug-17
BMS	IM011-047	Psoriasis	Sub-I	3	19-Jan-21
BMS	IM011-075	Psoriasis	Sub-I	3b	06-May-25
Boehringer Ingelheim	1297.9	Psoriasis	Sub-I	3	01-Jan-19
Centocor	C0168T45	Psoriasis	Sub-I	OBS	20-Jun-06
Dermavant	DMVT-505-3004	Psoriasis	Sub-I	3	11-Mar-26
Dermavant	DMVT-505-3003	Psoriasis	Sub-I	2/3	08-Jun-21
Genentech	ACD3101g	Psoriasis	Sub-I	3b	07-Oct-09
GSK	200853	Psoriasis	Sub-I	3	01-May-21
InventisBio	D2570-207	Psoriasis	Sub-I	2	ONGOING
Janssen	CNT01275PSO3013	Psoriasis	Sub-I	3	05-Oct-17
Janssen	CNT01959PSO3009	Psoriasis	Sub-I	3	30-Oct-18
Nimbus	4858-201	Psoriasis	Sub-I	2b	05-Dec-22
Novartis	CAIN457A2310	Psoriasis	Sub-I	3	31-Oct-18
Novartis	CAIN457A2313	Psoriasis	Sub-I	3b	04-Apr-17
Novartis	CAIN457A2326	Psoriasis	Sub-I	3	26-Sep-18
Novartis	CAIN457AUS07	Psoriasis	Sub-I	4	03-Jun-19
Novartis	CCJM112X2101	Psoriasis	Sub-I	1	26-Jan-16
Pfizer	A3921061	Psoriasis	Sub-I	3	11-Oct-16
Pfizer	A3921078	Psoriasis	Sub-I	3	06-Jan-14
Promius	DFD06-CD-005	Psoriasis	Sub-I	3	29-Aug-16
Schering Plough	PO5495	Psoriasis	Sub-I	2	30-Jan-13
Sienna	SNA-120-202	Psoriasis	Sub-I	2	01-Feb-19
Stiefel	STF115750	Psoriasis	Sub-I	1	30-Aug-17
Takeda	TAK279-3001	Psoriasis	Sub-I	3	20-Jan-26
Takeda	TAK279-3003	Psoriasis	Sub-I	3	ONGOING
Takeda	TAK-279-PsO-3004	Psoriasis	Sub-I	3	02-Jun-26
Abcentra	ORT-2020-01	Psoriasis	Sub-I	2	21-Feb-23

Scott A. Fretzin, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
AbGenomics	2012.005.01	Psoriasis	Sub-I	2a	15-Apr-14
AbGenomics	2014.002.01	Psoriasis	Sub-I	2	09-Apr-15
Amgen	20030106	Psoriatic Arthritis	PI	3	09-Nov-04
Celgene	CC-10004-PSA-004	Psoriatic Arthritis	PI	3	14-Dec-12
Janssen	CNT01275PSA3001	Psoriatic Arthritis	PI	3	06-Aug-13
Janssen	CNT01275PSA3002	Psoriatic Arthritis	PI	3	17-Jan-13
Janssen	CNT0148PSA3001	Psoriatic Arthritis	PI	3	08-Sep-15
Janssen	CNT01959PSA2001	Psoriatic Arthritis	PI	2a	01-Mar-17
Nimbus	4858-202	Psoriatic Arthritis	PI	2b	29-Mar-23
Novartis	CAIN457A02001B	Psoriatic Arthritis	PI	4	23-Jan-25
Novartis	CAIN457F2318	Psoriatic Arthritis	PI	3	06-Sep-18
Novartis	CAIN457P12302	Psoriatic Arthritis	PI	3	12-Sep-22
Abbvie	H15-457	Psoriatic Arthritis	Sub-I	OBS	25-Oct-17
Janssen	CNT01959PSA3001	Psoriatic Arthritis	Sub-I	3	10-Jul-18
Janssen	CNT01959PSA3002	Psoriatic Arthritis	Sub-I	3	10-Jul-18
Boehringer Ingelheim	1368-0140	Pyoderma Gangrenosum	PI	3	ONGOING
Merck	MK-0663-107	Rheumatoid Arthritis	PI	3	29-Jul-14
Cutanea	CLS001-CO-PR-006	Rosacea	PI	3	07-Mar-18
Perrigo	PRG-NY-14-022	Rosacea	Sub-I	3	17-Nov-15
Galderma	GLI.04.SPR.US10120	Rosacea	Sub-I	4	01-Nov-09
BMS	IM011-220	Scalp Psoriasis	PI	3b/4	19-Nov-24
Evidera	EVA-20371-01	Scalp Psoriasis	PI	OBS	11-Jan-24
Arcutis	ARQ-154-304	Seborrheic Dermatitis	Sub-I	3	06-Jul-22
Lilly	F1K-US-EVDO	Sepsis	Sub-I	4	01-Oct-09
Evidera	EVA-44850	Skin Tone Assessment	PI	OBS	ONGOING
Merck	009-00	Vaccine	PI	2	26-Feb-13
RXI	RXI-SCP-1502	Verruca Vulgaris	PI	2a	06-Sep-18
Abbvie	M19-044	Vitiligo	PI	3	ONGOING
Abbvie	M19-051	Vitiligo	PI	2	09-Nov-23
Abbvie	M25-264	Vitiligo	PI	3	ONGOING
Evidera	EVA-31203-01	Vitiligo	PI	OBS	31-Oct-22
Lilly	J5D-MC-FPAD	Vitiligo	PI	2	ONGOING
Merck	MK-6194-007	Vitiligo	PI	2a	20-May-25
Pfizer	B7981040	Vitiligo	PI	3	05-Mar-26
Pfizer	B7981041	Vitiligo	PI	3	ONGOING
Pfizer	B7981080	Vitiligo	PI	3	10-Sep-25
VYNE	VY2024-02	Vitiligo	PI	2b	30-Jul-25
DRG Abacus	8493	Vitiligo	Sub-I	OBS	01-Dec-20
Incyte	INCB18424-211	Vitiligo	Sub-I	2	28-Aug-20
Novartis	CGIA362B12201	Vitiligo	Sub-I	2	ONGOING
Cutanea	CLS006-CO-PR-002	Warts	PI	3	22-Jan-19
Aclaris	A-101-WART-202	Warts	Sub-I	2	11-Apr-18
Aclaris	A-101-WART-301	Warts	Sub-I	3	26-Nov-19
Acclaris	A-101-WART-303	Warts	Sub-I	3	29-Jan-20